GRO Biosciences
About GRO Biosciences
GRO Biosciences has developed a synthetic biology platform that utilizes non-standard amino acids (NSAAs) to enhance protein therapeutics, improving their potency, stability, and immunogenicity. The platform specifically targets the limitations of traditional protein therapies, enabling more effective treatments for autoimmune diseases.
```xml <problem> Traditional protein therapeutics are limited by the inherent properties of the 20 standard amino acids, which can restrict their potency, stability, and immunogenicity, hindering their effectiveness in treating diseases like autoimmune disorders. These limitations pose challenges in developing targeted and well-tolerated therapies. </problem> <solution> GRO Biosciences has developed a synthetic biology platform that expands the genetic code to incorporate non-standard amino acids (NSAAs) into protein therapeutics, overcoming the limitations of traditional protein therapies. The GRO platform enables precise control over protein glycosylation through ProGly™ NSAAs, allowing for the creation of novel protein structures and functionalities. By incorporating NSAAs, GRO Biosciences can enhance protein therapeutics to improve their potency, stability, and reduce immunogenicity. This approach allows for the development of more effective and targeted treatments, particularly in areas such as reversing autoimmunity and eliminating unwanted immune responses. </solution> <features> - Proprietary platform for incorporating non-standard amino acids (NSAAs) into proteins. - ProGly™ NSAAs for precise control over protein glycosylation. - Enhanced protein stability and reduced immunogenicity through NSAA incorporation. - Ability to re-educate the immune system to reverse autoimmune processes. - Development of novel protein therapeutics with improved potency. </features> <target_audience> The primary target audience includes pharmaceutical companies and research institutions focused on developing advanced protein therapeutics for autoimmune diseases and other conditions requiring improved protein properties. </target_audience> ```
What does GRO Biosciences do?
GRO Biosciences has developed a synthetic biology platform that utilizes non-standard amino acids (NSAAs) to enhance protein therapeutics, improving their potency, stability, and immunogenicity. The platform specifically targets the limitations of traditional protein therapies, enabling more effective treatments for autoimmune diseases.
Where is GRO Biosciences located?
GRO Biosciences is based in Boston, United States.
When was GRO Biosciences founded?
GRO Biosciences was founded in 2016.
How much funding has GRO Biosciences raised?
GRO Biosciences has raised 91450000.
- Location
- Boston, United States
- Founded
- 2016
- Funding
- 91450000
- Employees
- 33 employees
- Major Investors
- Access Biotechnology, Atlas Venture